Large-Scale Brain Network Dynamics Provide a Measure of Psychosis and Anxiety in 22q11.2 Deletion Syndrome.

BACKGROUND: Prodromal positive psychotic symptoms and anxiety are two strong risk factors for schizophrenia in 22q11.2 deletion syndrome (22q11DS). The analysis of large-scale brain network dynamics during rest is promising to investigate aberrant brain function and identify potentially more reliable biomarkers. METHODS: We retrieved and examined dynamic properties of large-scale functional brain networks using innovation-driven coactivation patterns. The study included resting-state functional magnetic resonance scans from 78 patients with 22q11DS and 85 healthy control subjects. After group comparison of temporal brain network activation properties, functional signatures of prodromal psychotic symptoms and anxiety were extracted using multivariate partial least squares correlation. RESULTS: Patients with 22q11DS had shorter activation in cognitive brain networks, longer activation in emotion processing networks, and generally increased segregation between brain networks. The functional signature of prodromal psychotic symptoms confirmed an implication of cingulo-prefrontal salience network activation duration and coupling. Further, the functional signature of anxiety uncovered an implication of amygdala activation and coupling, indicating differential roles of dorsal and ventral subdivisions of the anterior cingulate and medial prefrontal cortices. Coupling of amygdala with the dorsal anterior cingulate and medial prefrontal cortices was promoting anxiety, whereas coupling with the ventral anterior cingulate and medial prefrontal cortices had a protective function. CONCLUSIONS: Using innovation-driven coactivation patterns for dynamic large-scale brain network analysis, we uncovered patterns of brain network activation duration and coupling that are relevant in clinical risk factors for psychosis in 22q11DS. Our results confirm that the dynamic nature of brain network activation contains essential function to develop clinically relevant imaging markers of psychosis vulnerability.